スターリング・オンコロジー
STLN
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.13 | $170M | $9M |
| 2026 Q2 | -0.08 | $161M | $11M |
| 2026 Q1 | -0.02 | $147M | -$3M |
| 2025 Q4 | -0.06 | $142M | $2M |
| 2025 Q3 | -0.14 | $137M | -$13M |